Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1623 1624 1626
This examiner grants 100% of resolved cases
BAUER, BRIANNA LEE is an examiner in Tech Center 1600 and Art Unit 1611. This examiner has 1 resolved case. The allowance rate for these cases is 100.0%. The median days to allowance is 999. These metrics establish the baseline for prosecution in this art unit.
The interview lift is 0.0%. This figure shows the change in allowance probability when an interview is conducted. Practitioners can use the 0.0% lift and the 100.0% allowance rate to evaluate the utility of an interview. The 1 resolved cases provide the data for these prosecution trends.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706621 | COMPOSITIONS AND METHODS FOR REDUCING MASTER MIX CONTAMINATION | Non-Final OA | Life Technologies Corporation |
| 18599554 | HYDROXY ACIDS FOR SCALP AND HAIR IN PERSONAL CARE COMPOSITIONS | Non-Final OA | The Procter & Gamble Company |
| 18599579 | HYDROXY ACIDS FOR SCALP AND HAIR IN SULFATE FREE PERSONAL CARE COMPOSITIONS | Non-Final OA | The Procter & Gamble Company |
| 18694815 | SMALL MOLECULE INHIBITORS OF TEAD-YAP | Non-Final OA | The General Hospital Corporation |
| 18626665 | CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | Non-Final OA | Hoffmann-La Roche Inc. |
| 18705346 | CCR6 RECEPTOR MODULATORS | Non-Final OA | Idorsia Pharmaceuticals Ltd |
| 18601388 | IMIDAZOLE HETEROCYCLE BASED COMPOUNDS AND METHODS OF TREATING CANCER | Non-Final OA | King Abdulaziz University |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18707314 | COMPOUNDS HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | Non-Final OA | FUDAN UNIVERSITY |
| 18626052 | PROCESS FOR THE PRODUCTION OF (1R,2S,5R)-1-AMINO-5-[2-(DIHYDROXYBORANYL)ETHYL]-2-[(DIMETHYLAMINO)METHYL]-CYCLOHEXANE-1-CARBOXYLIC ACID | Non-Final OA | Molecure S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy